MItochondrial Intervention for Resilience in Older Adults With Coenzyme Q10
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age65+
SponsorUniversity Medical Centre Ljubljana
About this trial
This randomized, double-blind, placebo-controlled clinical trial will investigate whether 10 weeks of CoQ10 supplementation can improve biological resilience and functional health in community-dwelling adults aged 65 years or older with signs of reduced biological resilience or prefrailty.
Participants will be randomly assigned in a 1:1 ratio to receive either 200 mg of CoQ10 daily or matching placebo for 10 weeks. The study will assess the effects of CoQ10 supplementation on mitochondrial functional resilience, chronic low-grade inflammation, metabolic health, physical performance, cognitive function, and objective measures of skin aging.
The study will also investigate whether baseline biological and functional characteristics can identify individuals who are more likely to benefit from CoQ10 supplementation. An exploratory aim is to develop a multidimensional composite index of biological resilience integrating molecular, biochemical, functional, and clinical measures of aging.
The study will provide evidence on whether a mitochondria-targeted intervention with CoQ10 may represent a potential strategy for improving functional resilience and reducing features of prefrailty in older adults.
Eligibility criteria
Qualifiers
Age 65 years or older.
Community-dwelling older adult.
Prefrailty according to the Fried frailty phenotype, defined as the presence of 1-2 of the following criteria: unintentional weight loss, self-reported exhaustion, reduced physical activity, slow walking speed, or reduced handgrip strength; or
Reduced physical performance, defined as a Short Physical Performance Battery (SPPB) score of ≤9; or
Disqualifiers
Established frailty with severe functional impairment that would interfere with study participation or outcome assessment.
Advanced dementia or cognitive impairment preventing informed consent or reliable participation in study assessments.
Active malignant disease or ongoing cancer treatment.
Acute inflammatory disease or acute infection at the time of enrollment.
Trial design
Treatments tested in this trial
- Q10Vital® (CoQ10, ubiquinone)
- Placebo
Treatment groups
100 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov